The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation
- PMID: 17368771
- DOI: 10.1016/j.molimm.2007.01.036
The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation
Abstract
Hemolytic uremic syndrome is the clinical triad of thrombocytopenia, microangiopathic hemolytic anaemia and acute renal failure. Cases not associated with a preceding Shiga-like toxin producing Escherichia coli are described as atypical HUS (aHUS). Approximately 50% of patients with aHUS have mutations in one of three complement regulatory proteins, Factor H (CFH), membrane cofactor protein (MCP;CD46) or factor I (IF). A common feature of these three proteins is that they regulate complement by cofactor activity. Decay accelerating factor (DAF; CD55) regulates the complement system by disassociating the alternative and classical pathway convertases. Like CFH and MCP, the gene for DAF lies within the regulators of complement activation (RCA) gene cluster at 1q32. In 1998, we described linkage to this region in families with aHUS which led to the discovery of mutations in CFH and MCP. We therefore genotyped DAF in a panel of 46 aHUS patients including families with linkage to the RCA cluster. A mutation, I197V, was identified in one patient with familial HUS which was not found in 100 healthy controls. Molecular modelling of this mutation shows that the I197V mutation does not reside in an area which would be predicted to be important in decay accelerating activity. The expression of I197V on EBV-transformed B lymphocytes was equivalent to that of wild type controls. There was no significant decrease in decay acceleration activity of the recombinantly produced I197V mutant compared with wild type, as measured by a complement-mediated lytic assay. In conclusion, this study, identifies only one mutation in DAF in 46 patients with aHUS. This mutation, I197V, does not impair complement regulation and cannot be implicated in the pathogenesis of aHUS in this patient. This suggests that the complement regulatory abnormality in aHUS is principally one of deficient cofactor activity rather than of decay acceleration activity.
Similar articles
-
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.Hum Mutat. 2007 Mar;28(3):222-34. doi: 10.1002/humu.20435. Hum Mutat. 2007. PMID: 17089378
-
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.J Am Soc Nephrol. 2006 Jul;17(7):2017-25. doi: 10.1681/ASN.2005101051. Epub 2006 Jun 8. J Am Soc Nephrol. 2006. PMID: 16762990
-
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.Mol Immunol. 2007 Jan;44(1-3):111-22. doi: 10.1016/j.molimm.2006.07.004. Epub 2006 Aug 1. Mol Immunol. 2007. PMID: 16882452 Review.
-
Atypical haemolytic uraemic syndrome.Br Med Bull. 2006;77-78:5-22. doi: 10.1093/bmb/ldl004. Epub 2006 Sep 11. Br Med Bull. 2006. PMID: 16968692 Review.
-
The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts.J Med Genet. 2005 Nov;42(11):852-6. doi: 10.1136/jmg.2005.030783. Epub 2005 Mar 22. J Med Genet. 2005. PMID: 15784724 Free PMC article.
Cited by
-
Allelic variants of complement genes associated with dense deposit disease.J Am Soc Nephrol. 2011 Aug;22(8):1551-9. doi: 10.1681/ASN.2010080795. Epub 2011 Jul 22. J Am Soc Nephrol. 2011. PMID: 21784901 Free PMC article.
-
Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?Clin J Am Soc Nephrol. 2012 Mar;7(3):417-26. doi: 10.2215/CJN.05750611. Epub 2012 Jan 5. Clin J Am Soc Nephrol. 2012. PMID: 22223611 Free PMC article.
-
Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?J Am Soc Nephrol. 2014 Sep;25(9):2053-65. doi: 10.1681/ASN.2013070796. Epub 2014 Mar 20. J Am Soc Nephrol. 2014. PMID: 24652797 Free PMC article.
-
Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection.PLoS One. 2013 Sep 23;8(9):e74880. doi: 10.1371/journal.pone.0074880. eCollection 2013. PLoS One. 2013. PMID: 24086391 Free PMC article.
-
Complement Dysregulation and Disease: Insights from Contemporary Genetics.Annu Rev Pathol. 2017 Jan 24;12:25-52. doi: 10.1146/annurev-pathol-012615-044145. Epub 2016 Dec 5. Annu Rev Pathol. 2017. PMID: 27959629 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous